Giulia Bon

Cellular Therapeutics (United Kingdom) — United Kingdom

Medicine · Health Sciences

16h-index1.0kcitations69works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(30), Cancer Immunotherapy and Biomarkers(28), Lung Cancer Research Studies(24), HER2/EGFR in Cancer Research(10), Cell Adhesion Molecules Research(10)

Publications69 total

Supplementary Table S5 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S9 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Data from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Table S3 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S3 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S2 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S1 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S7 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S14 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S20 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S19 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Table S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Table S1 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S6 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S23 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S15 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S11 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S12 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S16 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
Supplementary Figure S21 from Transcriptional Phenocopies of Deleterious <i>KEAP1</i> Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024Open Access
page 1 of 4Next →

Frequent Co-authors

Marcello Maugeri‐Saccà(28), Gennaro Ciliberto(27), Stefano Scalera(22), Rita Falcioni(22), Daniele Marinelli(21), Ruggero De Maria(21), Giulia Schiavoni(20), Daniele Santini(19), Irene Terrenato(18), Federico Cappuzzo(18), Ludovica Ciuffreda(18), Biagio Ricciuti(17), Marco Mazzotta(17), Laura Cipriani(17), Alessandro Di Federico(17), Joao V. Alessi(17), Maurizio Fanciulli(17), Francesca De Nicola(17), Frauke Goeman(17), Giulio Caravagna(17)